These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 20056791)

  • 1. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
    van der Flier A; Hong V; Liu Z; Piepenhagen P; Ulinski G; Dumont JA; Orcutt KD; Goel A; Peters R; Salas J
    Blood Coagul Fibrinolysis; 2023 Sep; 34(6):353-363. PubMed ID: 37577860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
    Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
    J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
    Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
    Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric proteins comprising the constant region of immunoglobulins for treating hemophilia B (WO2005001025).
    Taupin P
    Expert Opin Ther Pat; 2011 Jun; 21(6):967-70. PubMed ID: 21476878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM
    Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
    Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
    Fukutake K; Kobayashi T; Sommer JM; Hirakata T
    Int J Lab Hematol; 2020 Apr; 42(2):162-169. PubMed ID: 31820573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Aug; 136(2):371-8. PubMed ID: 25840744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
    Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
    Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
    Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
    J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.
    Atsou S; Furlan F; Duchemin J; Ellouze S; Sourdeau É; Launois A; Roussel-Robert V; Stieltjes N; Combe S; Fontenay M; Curis E; Jourdi G
    Eur J Pharmacol; 2021 Jan; 891():173764. PubMed ID: 33249076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.